ChromaDex Corporation (CDXC)
| Market Cap | 451.46M |
| Revenue (ttm) | 62.01M |
| Net Income (ttm) | -23.26M |
| Shares Out | 67.99M |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 393,642 |
| Open | 6.83 |
| Previous Close | 6.70 |
| Day's Range | 6.30 - 6.87 |
| 52-Week Range | 4.36 - 23.66 |
| Beta | 1.73 |
| Analysts | Strong Buy |
| Price Target | 14.80 (+132.7%) |
| Est. Earnings Date | Nov 4, 2021 |
About CDXC
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of...
Financial Performance
In 2020, ChromaDex's revenue was $59.26 million, an increase of 28.01% compared to the previous year's $46.29 million. Losses were -$19.93 million, -38.02% less than in 2019.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ChromaDex stock is "Strong Buy." The 12-month stock price forecast is 14.80, which is an increase of 132.70% from the latest price.
News
ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wednesday, Nov. 3, 2021 at 4:30 p.m. ET to discuss its financial results ...
ChromaDex Comments on Jury Award Against Elysium Health and Reiterates Plans for Growth
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #cdxc--ChromaDex Corp. (NASDAQ:CDXC) today announced that a jury in the United States District Court for the Central District of California found that Elysium Heal...
ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChinaCrossBorder--ChromaDex Corp. (NASDAQ: CDXC) announced today a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. (“Sinopharm Xingsha”) to ...
ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Progra...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #nicotinamideriboside--ChromaDex Corp. (NASDAQ:CDXC) today announced findings from recently published preclinical studies, as well as recently registered clinical ...
Why ChromaDex Stock Is Sinking Today
The company lost a key patent infringement lawsuit but plans to appeal the court decision.
Why Are ChromaDex Shares Trading Lower On Wednesday?
ChromaDex Corp (NASDAQ: CDXC) dropped over 20% during the premarket despite its announcement over plans to appeal a court ruling issued by the U.S. District Court for the District of Delaware in a paten...
ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge's Ruling in Patent Inf...
LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) issued the following statement: ChromaDex announced today plans to appeal a September 14 decision granting a Motion for Summary Judgment (MSJ)...
ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates
ChromaDex (CDXC) delivered earnings and revenue surprises of 11.11% and 7.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex Corporation Reports Second Quarter 2021 Financial Results
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2021. Second Quarter 2021 and Recent Highlights Total net sale...
Analysts Estimate ChromaDex (CDXC) to Report a Decline in Earnings: What to Look Out for
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., August 3, 2021 at 4:30 p.m. ET to discuss its financial results fo...
CHROMADEX'S HEALTHY AGING PRODUCTS GAIN NEW TRACTION WITH FOUR HUGE DISTRIBUTION AGREEMENTS INCLUDING WALMART
ChromaDex Corp. (NASDAQ: CDXC) participated in a virtual presentation at the Benzinga Small Cap Conference in May 2021. ChromaDex CEO Rob Fried also presented on a panel discussing "Investing in Longevi...
ChromaDex Shares Research Findings from the ChromaDex External Research Program (CERP™)
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced the results of four recently published preclinical studies, highlighting new findings for its patented...
Why ChromaDex Stock Is Jumping Today
The company's flagship product was launched in Walmart stores across the U.S.
ChromaDex Shares Jump on Tru Niagen's Launch In Walmart Stores
ChromaDex Corp (NASDAQ: CDXC) has launched its flagship consumer product Tru Niagen in Walmart Inc (NYSE: WMT), available in 3,800 stores across the U.S. The NAD+ booster will be offered to Walmart cust...
ChromaDex and Walmart Launch Tru Niagen® in 3,800 Walmart Stores Across the United States
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) announced today the launch of its flagship consumer product Tru Niagen® in Walmart, available in 3,800 stores across t...
ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates
ChromaDex (CDXC) delivered earnings and revenue surprises of -33.33% and -10.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex Corporation Reports First Quarter 2021 Financial Results
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today reported first quarter 2021 financial results. First Quarter 2021 and Recent Highlights Total net sales of $14.7 mil...
ChromaDex and Ro Partner for New Product Development
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #collaboration--ChromaDex Corp. (NASDAQ:CDXC) announced today that it entered into a strategic supply agreement for Niagen® with Ro, a healthcare-technology compan...
ChromaDex to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 6, 2021 at 4:30 p.m. ET to discuss its financial results for ...
ChromaDex and Health & Happiness (H&H) Group Announce Supply Agreement for Niagen®
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a strategic supply agreement with Health & Happiness (H&H) Group, a global leader in p...
ChromaDex Appoints Fadi Karam as Chief Marketing Officer
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #management--ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Fadi Karam as Chief Marketing Officer. Karam has spent his career driving consumer...
ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #collaboration--ChromaDex Corp. (NASDAQ: CDXC) today announced a new research initiative with the Citrin Foundation of Singapore to study the effects of Niagen® ni...
ChromaDex to Present at the Lytham Partners Spring 2021 Investor Conference
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenti...
Is the Options Market Predicting a Spike in ChromaDex (CDXC) Stock?
Investors need to pay close attention to ChromaDex (CDXC) stock based on the movements in the options market lately.